← 홈

Antibody

712개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 712개
AntibodystaleJazz PharmaceuticalsPhase 2

Zanidatamab (ZW25, ZW25 (Zanidatamab))

HER2+/HR+ Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 34%임상시험 31상태 ACTIVE
AntibodystaleJiangsu Hansoh Pharmaceutical C…Phase 2

adebrelimab and chemotherapy (adebrelimab and chemotherapy)

Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer · Efficacy and Safety of Neoadjuvant Immun

#EfficacyandSafetyofNeoadjuvantIm#Antibody#Phase2#항체#면역항체+2
임상시험 31상태 RECRUITING
AntibodystaleQuantumLeap Healthcare Collabor…Phase 2

AMG 479 (AMG 479, Ganitumab, AMG 479 (Ganitumab) plus Metformin)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 27%임상시험 30상태 RECRUITING
AntibodystaleRochePhase 3

trastuzumab (Herceptin, Docetaxel combined + Trastuzumab +Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 91.8%임상시험 30상태 RECRUITING
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Docetaxel combined with Trastuzumab±Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 91.8%임상시험 30상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab plus Olaparib)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 55.1%임상시험 30상태 RECRUITING
AntibodystaleGilead SciencesPhase 2

Magrolimab (Magrolimab)

Solid Tumor; Colorectal Cancer · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.7%임상시험 30상태 DISCONTINUED
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Pertuzumab Plus Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 69.3%임상시험 30상태 ACTIVE
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Pyrotinib Plus Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2
임상시험 30상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

Ramucirumab+ paclitaxel (Ramucirumab+ paclitaxel)

Gastric Cancer; Gastroesophageal Junction Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase3#항체#면역항체+3
효능 ORR 58.2%임상시험 30상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab, Lapatinib)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 50%임상시험 30상태 ACTIVE
AntibodystaleJazz PharmaceuticalsPhase 3

Zanidatamab (Zanidatamab)

HER2-positive Breast Cancer; Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+4
효능 ORR 34%임상시험 30상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Oleclumab (Oleclumab)

Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.5%임상시험 28상태 RECRUITING
AntibodystaleZhiyong YuPhase 2

Inetetamab (Inetetamab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 26상태 ACTIVE
AntibodystaleRochePhase 2

CapeOX + bevacizumab (CapeOX + bevacizumab)

Unresectable Metastatic Colorectal Cancer; Microsatellite Stable (MSS) Colorectal Cancer (CRC) · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+4
임상시험 25상태 RECRUITING
AntibodystaleRegeneronPhase 2

Cemiplimab plus REGN3767 (Cemiplimab plus REGN3767)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 23상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 76%임상시험 23상태 DISCONTINUED
AntibodystalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#항체#면역항체+5
효능 ORR 33.3%임상시험 23상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 3

zolbetuximab (zolbetuximab)

Gastric Cancer; Gastroesophageal Junction Adenocarcinoma · Locally Advanced Unresectable Gastroesop

#LocallyAdvancedUnresectableGastr#Antibody#Phase3#항체#면역항체+4
효능 ORR 48.1%임상시험 23상태 RECRUITING
AntibodystaleDiwakar DavarPhase 2

Domvanalimab (Domvanalimab)

Melanoma · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING

4 / 36 페이지

← 이전다음 →